Fulgent Genetics Inc (NASDAQ: FLGT)’s stock price has dropped by -2.51 in relation to previous closing price of 18.32. Nevertheless, the company has seen a gain of 3.06% in its stock price over the last five trading days. businesswire.com reported 2025-04-10 that EL MONTE, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question.
Is It Worth Investing in Fulgent Genetics Inc (NASDAQ: FLGT) Right Now?
The 36-month beta value for FLGT is also noteworthy at 0.94. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for FLGT is 19.88M, and at present, short sellers hold a 7.64% of that float. The average trading volume of FLGT on April 18, 2025 was 451.17K shares.
FLGT’s Market Performance
FLGT’s stock has seen a 3.06% increase for the week, with a 5.87% rise in the past month and a 2.06% gain in the past quarter. The volatility ratio for the week is 4.98%, and the volatility levels for the past 30 days are at 4.32% for Fulgent Genetics Inc The simple moving average for the last 20 days is 2.07% for FLGT’s stock, with a simple moving average of -8.73% for the last 200 days.
Analysts’ Opinion of FLGT
Many brokerage firms have already submitted their reports for FLGT stocks, with UBS repeating the rating for FLGT by listing it as a “Neutral.” The predicted price for FLGT in the upcoming period, according to UBS is $35 based on the research report published on December 07, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see FLGT reach a price target of $40, previously predicting the price at $65. The rating they have provided for FLGT stocks is “Neutral” according to the report published on December 08th, 2022.
Raymond James gave a rating of “Outperform” to FLGT, setting the target price at $45 in the report published on November 18th of the previous year.
FLGT Trading at 4.93% from the 50-Day Moving Average
After a stumble in the market that brought FLGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.87% of loss for the given period.
Volatility was left at 4.32%, however, over the last 30 days, the volatility rate increased by 4.98%, as shares surge +5.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.06% upper at present.
During the last 5 trading sessions, FLGT rose by +3.06%, which changed the moving average for the period of 200-days by -10.88% in comparison to the 20-day moving average, which settled at $17.50. In addition, Fulgent Genetics Inc saw -3.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FLGT starting from Kim Paul, who purchase 100,000 shares at the price of $15.96 back on Mar 05 ’25. After this action, Kim Paul now owns 348,282 shares of Fulgent Genetics Inc, valued at $1,596,470 using the latest closing price.
Xie Jian, the President and COO of Fulgent Genetics Inc, sale 1,455 shares at $19.50 during a trade that took place back on Dec 03 ’24, which means that Xie Jian is holding 334,681 shares at $28,372 based on the most recent closing price.
Stock Fundamentals for FLGT
Current profitability levels for the company are sitting at:
- -0.26 for the present operating margin
- 0.36 for the gross margin
The net margin for Fulgent Genetics Inc stands at -0.15. The total capital return value is set at -0.06. Equity return is now at value -3.76, with -3.38 for asset returns.
Based on Fulgent Genetics Inc (FLGT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 2.49. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -329.99.
Currently, EBITDA for the company is -73.92 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 1.78. The receivables turnover for the company is 3.68for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.85.
Conclusion
In summary, Fulgent Genetics Inc (FLGT) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
